T.way: the ideal port for diabetes management
T.way was designed to enable people with diabetes to take care of themselves, thus living their daily life with confidence and trust.
1
T.way
The medical device for the subcutaneous administration of insulin diminishing the frequency and inconvenience of injections, while ensuring comfort and freedom thanks to its design.
2
T.bridge
Multi-use device for the automatic, simple and painless application of T.way.
Comfort and freedom
for your children
T.way offers several advantages for children and parents:
Minimum age 1 year.
Compatible with the different sizes of insulin pens and syringes for easy delivery.
It can be used up to a maximum of 72 hours, for long-lasting comfort.
Find out T.way functions
Precise, discreet and flexible
Don’t give up your freedom; T.way allows you to reduce the number of insulin injections, while increasing administration precision. Find out all its advantages in your daily life.
- INJECTIONS
+ FREEDOM
It drastically reduces the number of necessary injections vs. the traditional MDI therapy (1 vs. 15 in 3 days): treatment with less needle pricks is possible.
- INVASIVITY
+ FLEXIBILITY
It ensures comfort and flexibility as it is water and dust resistant (IP68): the freedom of performing your daily activities in a relaxed and safe manner.
- THICKNESS
+ DISCRETION
It is very discreet thanks to the various application sites and to its small size, which makes it the thinnest devices in its class: thus ensuring both physical and psychological comfort.
- VOLUME
+ PRECISION
It proves more precise in dosing the administered therapy thanks to the very low residual value (0.1 U)1 it ensures: an important detail that can make the difference.
For healthcare professionals and all the patients that rely on our technologies.
Access the T.care portal, always available to you
T.way is a CE0051-certified medical device. T.bridge is a certified medical device.
Please, read the directions or instructions for use carefully
- Reference to the comparison with in-silico data about the minimum insulin dose necessary to promote a change, as defined in the clinically relevant trial, in blood glucose concentration [Journal of Diabetes Science and Technology 2018, Vol. 12(2) 376–380].